Board of Directors
Education: M.D. 1986 Lund University, Ph.D. 1991 Lund University, Professor 2019 University of Gothenburg.
Experience and prior assignments: Professor Bertil Lindmark has a long and successful career in bio pharma with leading global roles in AstraZeneca and Almirall as well as in several biotech companies. His focus in respiratory, immunology and cancer has led to global drug approvals and successful launches. He has also been involved in several IPOs, major funding events and acquisitions.
Other current assignments: Chief Medical Officer of Galecto Inc., non-executive board member of ALK-Abelló A/S.
Holdings: 23,688 shares.
Education: Medical degree 1981 at Lund University, Specialist in General Surgery 1987, Professor of Surgery at the School of Medicine, Lund University in 2000.
Experience and prior assignments: Professor Andersson’s clinical work and research focuses on malignancies of the pancreas, liver and biliary tract. He also leads a translational research group with a focus on development of novel biomarker panels for diagnosis, prognosis, assessment, treatment selection and outcomes, as well as on increasing knowledge of the disease itself. He has published about 500 original articles, reviewed articles and book chapters, and supervised 30 Ph.D. students. He also has an extensive international network and has founded six companies in his role as an entrepreneur.
Other current assignments: Chairman of the Board of Reccan Diagnostics AB, Nordic Biotechnology AB and Board member of Lumito AB.
Holdings: 40,718 shares privately and through company.
Education: Economics degree from the University of Copenhagen in 1989.
Experience and prior assignments: Anders Kronborg is formerly COO at Kinnevik Investments AB. 2015-2022 CFO/ interim CEO at LEO Pharma. Experience from pharma transactions, both early and late stages.
Other current assignments: CEO in Resother Pharma.
Education: PhD in molecular signaling from Lund University, postdoc training from the Broad Institute of MIT and Harvard and Executive MBA at the MIT Sloan School of Management, 2023.
Experience and prior assignments: Kristina Masson is co-founder, Board member and EVP Business Operations of Acrivon Therapeutics Inc., an American biotechnology and recently listed NASDAQ company. She is the founder and CEO of its Swedish subsidiary Acrivan AB, with a focus on early pharmaceutical research.
Other current assignments: CEO of Acrivan AB, EVP and Board member of Acrivon Therapeutics Inc.
Education: B.Sc., Business Administration, Lund University 1992.
Experience and prior assignments: Martin Olovsson is CEO of OnDosis, a medtech/healthtech company which he co-founded in 2017. Before this, Martin acquired many years of managerial experience in the pharmaceutical industry with responsibility for portfolio and product strategies, life cycle management, bridging functions such as science and marketing and ensuring commercial excellence. Martin has extensive experience from in- and out-licensing of both pharmaceuticals and technologies. Between 1992 and 2017 he held several international positions within AstraZeneca, including President of the Nordic/Baltic marketing company and Global Vice President of Inhaled Respiratory franchise.
Other current assignments: CEO of OnDosis. Board member of WntResearch AB and IP Enabler AB.
Holdings: 21,108 shares.
Education: Executive MBA, EFL (Executive Foundation Lund), as well as studies in marketing and communication at Lund University.
Experience and prior assignments: Gunilla Savring has many years of experience from leading positions in management and investor relations at development and growth companies such as Axis Communications, Precise Biometrics and Clinical Laserthermia Systems within the IT, pharmaceutical and chemical technology sector. She has also experience from serving on the board of several listed companies.
Other current assignments: CEO and senior consultant in her own company. Board member of aXichem AB and Incendia AB.
Holdings: 2,364 shares through company.